NCT05667636 (esSBRT) is a Phase 2 clinical trial of salvage SBRT in Prostatic Neoplasm, sponsored by Regina Elena Cancer Institute.

Who is sponsoring NCT05667636?

NCT05667636 is sponsored by Regina Elena Cancer Institute.

What drugs are being tested in NCT05667636?

Interventions in NCT05667636: salvage SBRT.

What condition does NCT05667636 study?

NCT05667636 studies Prostatic Neoplasm.

Is NCT05667636 still recruiting?

NCT05667636 is currently status unknown. Last updated 28 December 2022.

Last reviewed 2022-12-28 · How we verify

NCT05667636: esSBRT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Salvage Stereotactic Radiotherapy for Biochemical Failure After RP

Status unknown Phase 2 Last updated 28 December 2022

What this trial tests

Phase 2 trial testing salvage SBRT in Prostatic Neoplasm in 103 participants. Status unknown.

Timeline

27 September 2022

Primary endpoint
27 September 2023

27 September 2024

Quick facts

Lead sponsor	Regina Elena Cancer Institute
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	103
Start date	27 September 2022
Primary completion	27 September 2023
Estimated completion	27 September 2024
Sites	1 location across Italy

Drugs / interventions tested

salvage SBRT

Conditions studied

Prostatic Neoplasm — all drugs for Prostatic Neoplasm →

Sponsor

Regina Elena Cancer Institute

Who can join

18 and older, male only, with Prostatic Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

After radical prostatectomy, 30-60% of patients will develop recurrent disease. Salvage radiotherapy, usually at 2 Gy per fraction, is the main treatment option for these patients. The aim of the present study is to determine the 3-yr biochemical failure free survival of the stereotactic approach in 5 fractions in the context of salvage radiotherapy for biochemical failure after radical prostatectomy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Salvage stereotactic body radiotherapy for post-prostatectomy recurrence: are we almost there?
Chen Z, Tran VT, Matsuda M, Akita T, et al · · 2026 · PMID 41734055 · DOI 10.1093/jrr/rrag006

Verify or expand the search:

Other recruiting trials for Prostatic Neoplasm

Currently open trials in the same condition.

NCT07084779 — Investigation of Impact of AI on Prostate Cancer Workflow · NA · recruiting
NCT05968144 — Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness · Phase 1, PHASE2 · active not recruiting
NCT05849298 — A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC · Phase 2 · active not recruiting
NCT06292897 — Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression · recruiting
NCT06046131 — Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression. · NA · recruiting

Other Regina Elena Cancer Institute trials

Trials by the same sponsor.

NCT07256769 — Vitamin k, D-chiro Inositol and α-lactalbumin in Bone Homeostasis · recruiting
NCT07248878 — Pilot Study for the Generation of Cervical Cancer Organoids From Patients Undergoing Diagnostic Biopsy · recruiting
NCT07258186 — Generation of Endometrial Carcinoma Organoids · recruiting
NCT07018037 — Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma · recruiting
NCT06894628 — Genomics and Efficacy of Post-prostatectomy Salvage Radiotherapy With 'Extreme' Hypofractionation · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05667636 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Regina Elena Cancer Institute
Last refreshed: 28 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05667636.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing